# Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

> **NCT03634241** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage I Lung Cancer AJCC v8
- Stage IA1 Lung Cancer AJCC v8
- Stage IA2 Lung Cancer AJCC v8
- Stage IA3 Lung Cancer AJCC v8
- Stage IB Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage IIA Lung Cancer AJCC v8
- Stage IIB Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT03634241
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2026-01-27
- **Final completion:** 2026-03-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634241, "Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03634241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*